A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Case Comprehensive Cancer Center
Bold Therapeutics, Inc.
J-Pharma Co., Ltd.
Sun Yat-sen University
TransThera Sciences (Nanjing), Inc.
Memorial Sloan Kettering Cancer Center
Jazz Pharmaceuticals
Merck Sharp & Dohme LLC
Shandong Cancer Hospital and Institute
First Affiliated Hospital of Zhejiang University
Lisata Therapeutics, Inc.
Shanghai Junshi Bioscience Co., Ltd.